Protease-Cleavable Prodrug Linker for Tumor-Targeted Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug molecules, particularly anti-cancer agents like T-cell engager drugs, often cause severe adverse effects such as cytokine release syndrome and on-target/off-tumor toxicity due to rapid peak concentrations and systemic distribution, leading to poor patient compliance and increased healthcare strain.
Innovation Solution
Development of conditionally activatable prodrugs with a protease-cleavable peptide linker that connects a drug molecule to a binding moiety, allowing the drug to remain inactive until cleaved by tumor-associated proteases, thereby localizing the active drug to the tumor site and reducing systemic toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a T-cell engager drug is administered systemically, then it can bind to tumor cells and activate T-cells, but it causes severe adverse effects such as cytokine release syndrome and on-target/off-tumor toxicity due to rapid peak concentrations and systemic distribution
Solution Approach 1:
The drug is divided into two separate components: a T-cell engager molecule and a cell-penetrating peptide (CPP). The T-cell engager remains in circulation without causing toxicity, while the CPP is delivered separately and enters cells only at the tumor site where both components are present, enabling localized activation and reducing systemic adverse effects
Solution Approach 2:
The cell-penetrating peptide is designed to be active only in the tumor microenvironment where it can penetrate cell membranes. This creates a localized effect at the tumor site while the T-cell engager remains in the bloodstream, ensuring that T-cell activation occurs only where needed and minimizing off-target toxicity
2Object-affected harmful factors
If the drug is administered in multiple doses or via continuous IV infusion to mitigate adverse effects, then systemic toxicity is reduced, but patient compliance deteriorates and healthcare strain increases
Solution Approach 1:
The cell-penetrating peptide acts as an intermediary that carries the T-cell engager into tumor cells locally. This single-administration approach achieves sustained therapeutic effect at the tumor site without requiring repeated dosing or continuous infusion, thereby improving patient compliance while maintaining reduced systemic toxicity
3Power
If the drug molecule is designed to bind simultaneously to tumor-associated antigen and CD3 receptors, then potent anti-tumor activity is achieved, but on-target/off-tumor recruitment of T-cells occurs causing severe toxicity
Solution Approach 1:
The cell-penetrating peptide function is extracted and separated from the T-cell engager molecule. The T-cell engager retains its binding function for tumor cells and T-cells without the membrane-penetrating capability, preventing systemic toxicity. The CPP is delivered separately and only penetrates tumor cell membranes at the tumor site, eliminating off-tumor recruitment while maintaining potent anti-tumor activity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach minimizes adverse effects and maintains therapeutic efficacy by ensuring the drug is only active at the tumor site, reducing systemic toxicity and improving treatment outcomes while maintaining potency.
Implementation Method 1
a protease-cleavable peptide linker that connects a drug molecule to a binding moiety, allowing the drug to remain inactive until cleaved by tumor-associated proteases
Data Source
AI summary
The application relates to prodrugs comprising a drug molecule connected by a protease-cleavable peptide linker to a binder, which reversibly inhibits a biological activity of the drug molecule, and to the inhibitory binders themselves. Also described are nucleic acids encoding the recombinant proteins described herein, and methods of making said recombinant proteins, as well as methods of treatment and medical uses of the recombinant proteins.